SHANGHAI, Feb. 22 WuXi PharmaTech (NYSE: WX), aleading pharmaceutical, biotechnology and medical device research anddevelopment outsourcing company with operations in China and the United States,announced today that its Suzhou non-clinical safety testing facility receivedfull accreditation from the Association for the Assessment and Accreditationof Laboratory Animal Care International (AAALAC). As a result of an extensiveon-site evaluation, AAALAC determined that WuXi PharmaTech's facility meetsthe highest standards of animal care and research practices.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
AAALAC is a private, nonprofit organization that promotes the humanetreatment of animals in science through voluntary accreditation and assessmentprograms. It evaluates all aspects of an animal care and use program,including institutional policies, animal husbandry, veterinary care and thephysical plant. In its evaluations, it relies on widely accepted guidelines,such as the Guide for the Care and Use of Laboratory Animals and otherreference resources, as well as its own position statements and Rules ofAccreditation.
"AAALAC accreditation establishes that our Suzhou facility meetsinternational standards of animal care," said Dr. Ge Li, Chairman and ChiefExecutive Officer of WuXi PharmaTech. "This accreditation continues todemonstrate WuXi's ability to provide our global customers with high qualityservice in a regulatory compliant environment. We believe that China willbecome a major market for non-clinical safety testing services over the nextdecade, and our company aims to become a leading provider of such services inChina. At 314,000 square feet and 108 animal rooms, our Suzhou facility is thelargest in China.
"We have built world-class facilities not just in Suzhou but throughoutour organization," Dr. Li continued. "Developing this new toxicology servicecapability further broadens our integrated service platform across drugdiscovery and preclinical development. Our mission is to help our customers toimprove the success of discovery and shorten the time of development."For more information, please contact: Ronald Aldridge Director of Investor Relations WuXi PharmaTech (Cayman) Inc. Tel: +1-201-585-2048 Email: Ron_Aldridge@wuxiapptec.com Stephanie Liu Associate Director of Corporate Communications Department Tel: +86-21-5046-4362 Email: firstname.lastname@example.org Web: http://www.wuxiapptec.com
SOURCE WuXi PharmaTech (Cayman) Inc.